Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to $8.7 million.

  • Heron Therapeutics' Accumulated Expenses rose 254.37% to $8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year increase of 254.37%. This contributed to the annual value of $9.6 million for FY2024, which is 357.76% up from last year.
  • According to the latest figures from Q3 2025, Heron Therapeutics' Accumulated Expenses is $8.7 million, which was up 254.37% from $6.5 million recorded in Q2 2025.
  • Heron Therapeutics' 5-year Accumulated Expenses high stood at $16.3 million for Q2 2022, and its period low was $6.5 million during Q1 2025.
  • Over the past 5 years, Heron Therapeutics' median Accumulated Expenses value was $9.6 million (recorded in 2021), while the average stood at $10.8 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first surged by 2684.6% in 2022, then crashed by 3961.89% in 2023.
  • Heron Therapeutics' Accumulated Expenses (Quarter) stood at $15.3 million in 2021, then decreased by 12.1% to $13.4 million in 2022, then tumbled by 31.25% to $9.2 million in 2023, then rose by 3.58% to $9.6 million in 2024, then fell by 8.44% to $8.7 million in 2025.
  • Its last three reported values are $8.7 million in Q3 2025, $6.5 million for Q2 2025, and $6.5 million during Q1 2025.